Apellis (NASDAQ: APLS) CTO Nur sells 2,618 shares to cover taxes stock

Rhea-AI Filing Summary

Apellis Pharmaceuticals' Chief Technical Officer Nur Nicholson reported a sale of company stock. On January 13, 2026, Nicholson sold 2,618 shares of Apellis common stock at a price of $22.1872 per share. According to the disclosure, these shares were sold to cover tax withholding on Restricted Stock Units that were released on January 12, 2026, meaning the transaction was tied to an equity award rather than an open-market discretionary sale of the full grant.

After this tax-related sale, Nicholson beneficially owned 81,046 shares of Apellis common stock in direct ownership. The filing is made as a Form 4, which reports changes in insider ownership for officers, and confirms Nicholson’s role as Chief Technical Officer of Apellis Pharmaceuticals, Inc.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nicholson Nur

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/13/2026		S(1)		2,618	D	$22.1872	81,046	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 12, 2026.

	/s/ David Watson, attorney-in-fact for Nur Nicholson	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Apellis (APLS) report for Nur Nicholson?

The filing reports that Chief Technical Officer Nur Nicholson sold 2,618 shares of Apellis common stock on January 13, 2026, as shown in Table I of the Form 4.

At what price were the Apellis (APLS) shares sold in this Form 4?

The reported sale price was $22.1872 per share for the 2,618 shares of Apellis common stock sold by CTO Nur Nicholson.

Why did Nur Nicholson sell Apellis (APLS) shares according to the Form 4 footnote?

The footnote explains that the sale represents shares sold to cover tax withholding on Restricted Stock Units that were released on January 12, 2026.

How many Apellis (APLS) shares does Nur Nicholson own after this transaction?

Following the reported sale, Nur Nicholson beneficially owned 81,046 shares of Apellis common stock in direct ownership, as disclosed in the Form 4.

What is Nur Nicholson’s role at Apellis (APLS) in this insider filing?

In the Form 4, the reporting person is identified as an officer of Apellis Pharmaceuticals, Inc., with the title Chief Technical Officer.

Is this Apellis (APLS) Form 4 filed by multiple reporting persons?

No. The Form 4 indicates that it is filed by one reporting person, namely Nur Nicholson, who is the company’s Chief Technical Officer.